Inhaled mRNA developer Ethris and CDMO Evonik have announced a new partnership for development and commercialization of a lipid nanoparticle (LNP) platform for delivery of nucleic acid. Ethris’s SNaP LNP technology will become available to Evonik customers, and Evonik will provide process development, formulation, and manufacturing services. The announcement notes that the Ethris technology “enables efficient lung targeting through high-energy aerosolization — an approach that has traditionally been difficult with conventional LNPs.”
Earlier this year, Ethris announced that it had partnered with Lonza on development of spray-dried formulations of intranasal mRNA-based vaccine candidates. Ethris’s ETH47 intranasal mRNA therapy is currently in Phase 2 development for the treatment of asthma, and the company is developing several inhaled and nasal formulations for the treatment of primary ciliary dyskinesia, as well as an intranasal vaccine against influenza.
Evonik Global Product Line Head, Parenteral Drug Delivery Solutions, J.P. Milde commented, “Our partnership with Ethris strengthens our portfolio and tackles key challenges in nucleic acid delivery. Ethris’ SNaP LNP technology improves thermostability, enabling storage at higher temperatures, and enhances local retention, facilitating targeted delivery to the site of action and prolonged presence where therapeutic effect is needed. We’re excited to offer this transformative solution to our customers.”
Ethris CEO Carsten Rudolph commented, “By combining our innovative nucleic acid delivery platforms with Evonik, one of the world’s leading CDMOs for LNP formulations, we are creating a powerful offering for pharma partners. This collaboration addresses the increasing demand for scalable, high-quality nucleic acid technologies and enables us to serve a broader set of partners worldwide. We will also benefit from Evonik’s expertise as we continue advancing our in-house mRNA therapeutics and vaccine pipeline.”
Read the Ethris and Evonik press release
